Ibogaine is a psychoactive alkaloid derived from Tabernanthe iboga, a plant used in initiatory rituals in West
Central Africa. Largely because of ibogaine’s status as a Schedule I substance in the U.S., the development of ibogaine’s
use in the treatment of drug addiction took place outside conventional clinical and medical settings. This article reviews
the history of ibogaine’s use in the treatment of drug addiction, and discusses progress made towards, and obstacles
blocking, the establishment of controlled clinical trials of ibogaine’s efficacy. Preclinical research has generally supported
anecdotal claims that ibogaine attenuates withdrawal symptoms and reduces drug cravings. Concerns about ibogaine’s
safety, as well as a dearth of solid data from human studies, have hampered progress in its development as an approved
medication. This article outlines major findings from preclinical studies, discusses concerns about ibogaine’s safety, and
details previous and ongoing research on ibogaine’s use as an anti-addictive treatment for humans.
Addiction, addiction treatment, drug abuse, ibogaine, iboga alkaloid, psychedelics, substance-related disorders.
University of California, San Diego, 9500 Gilman Drive, Mail Code 0311, La Jolla, CA 92093-0311, USA.